China Brain Cancer Therapeutics Market

China Brain Cancer Therapeutics Market Executive Summary

China Brain Cancer Therapeutics Market valued at $185 Mn in 2022, projected to reach $461 Mn by 2030 with a 12.1% CAGR.

The abnormal proliferation of brain cells serves as an indication of brain cancer, where these cells exhibit characteristics that can be either malignant (cancerous) or benign (non-cancerous). While the exact cause of brain cancer remains unclear, identified risk factors include exposure to ionizing radiation and a family history of brain tumors. Common symptoms associated with a brain tumor include headaches, gradual sensory decline, issues with balance, speech impediments, and hearing difficulties. The manifestation of these symptoms varies depending on factors such as the tumor’s size, location, and growth rate. Treatment approaches for brain cancer are determined by the tumor’s type, location, and size, with frequently utilized methods including radiosurgery, chemotherapy, radiotherapy, surgery, and the use of carmustine implants.

The burden of primary malignant brain tumors in China is notable, with an alarming incidence of over 241,000 new cases reported, reflecting an average of approximately 650 diagnoses per day. In the broader context, the cumulative count of new cases of brain and other nervous system tumors in China for the year 2022 stands at 246,129. Gliomas, a category of tumors affecting glial cells, particularly glioblastoma multiforme (GBM), have emerged as the most prevalent type of brain tumor in China, mirroring global trends. The prominence of gliomas, known for their aggressiveness and challenging prognosis, emphasizes the critical need for intensified efforts in early detection, advanced treatment modalities, and ongoing research initiatives to comprehensively address the complex landscape of primary malignant brain tumors in the Chinese population.

For the treatment of recurrent glioblastoma multiforme (GBM), Innovent Pharmaceuticals is presently undertaking a Phase IIb trial using fruquintinib (FG-1901). In addition, a Phase I/II trial for temozolomide plus IBI328, a PD-1/TIM3 bispecific antibody, for newly diagnosed GBM began in December 2023. Conversely, CStone Pharmaceuticals started a Phase I/II trial for CS1022, a PARP inhibitor, in December 2023, to treat advanced glioma. Concurrently, a Phase III trial is being conducted for SINU-5877, a repolarization drug intended to improve cognitive function in patients with glioblastoma multiforme following radiation therapy; the trial is anticipated to conclude in the third quarter of 2024. While data are still pending, BeiGene has concluded a Phase II trial using tislelizumab (BGBR315) in conjunction with chemotherapy for recurrent GBM.

Market Dynamics

Market Growth Drivers

Rising Burden of Brain Cancer: China's substantial and aging population heightens the likelihood of brain cancer development, with glioma, the predominant type, experiencing a 3.7% increase in incidence from 2000 to 2014. Increased case identification and a rise in treatment demand are both impacted by improved early diagnosis rates.

Growing Awareness and Demand for Improved Treatment Outcomes: Media campaigns and patient advocacy groups are driving the public's growing awareness of brain cancer and the variety of treatment options available. Patients are becoming more and more motivated to seek longer survival times and higher quality of life, which is fuelling the desire for more effective treatments.

Technological Advancements and Drug Pipeline: Pharmaceutical companies in China are proactively allocating resources to research and development efforts aimed at creating innovative drugs for brain cancer, with a specific focus on targeted therapies and immunotherapies. The rise in clinical trials for these promising new drugs not only expands the pool of potential treatments but also provides a broader range of options for patients. Furthermore, the local production of generic versions of well-established drugs is contributing to a reduction in costs and overcoming accessibility barriers, ensuring a more widespread availability of these critical treatments.

Market Restraints

Cost and Affordability: Newly developed immunotherapies and tailored treatments often come with high costs, making them unavailable to many patients, especially those living in rural areas. Even if more people have access to healthcare insurance, the costs of expensive new medications or cutting-edge treatment plans could not be fully covered. Patients frequently incur significant out-of-pocket expenses, which can cause financial hardship and, in rare circumstances, lead to treatment termination.

Limited Efficacy of Current Treatments: The effectiveness of current treatments for brain cancer might be constrained, emphasizing the necessity for groundbreaking innovations to markedly enhance patient outcomes. This constraint could potentially influence the market prospects of presently available drugs.

Regulatory Hurdles: The rigorous regulatory demands and approval procedures may present obstacles in the development and introduction of novel drugs for brain cancer treatment, potentially causing delays in their market entry.

Healthcare Policies and Regulatory Landscape

In China, healthcare policies and regulatory oversight for treatment drugs are principally administered by the National Medical Products Administration (NMPA), formerly known as the China Food and Drug Administration (CFDA). The NMPA plays a pivotal role in evaluating and approving the marketing of pharmaceuticals, ensuring their safety, efficacy, and quality. Regulatory approval from the NMPA is also required for conducting clinical trials, with a focus on upholding ethical and safety standards. Additionally, the NMPA enforces Good Manufacturing Practices (GMP) to maintain the quality and consistency of pharmaceutical manufacturing. The pricing and reimbursement of treatment drugs in China are influenced by the National Healthcare Security Administration (NHSA), reflecting the government's involvement in negotiating pricing and reimbursement policies.

Competitive Landscape

Key Players

• Innovent
• Hutchison MediPharmaceuticals
• China Resources Pharmaceutical Group (CRPG)
• BeiGene
• Hansoh Pharmaceutical Group Co.
• Zhejiang Hisun Pharmaceutical Co.
• Yishuntai Pharmaceuticals Group Co.
• Jiangsu Hengrui Medicine Co.
• Shanghai Junsun Science & Technology Co.
• Guangzhou Institute of Biopharmaceutical Technology (GIBT)